MARKET

MEOBF

MEOBF

Mesoblast
OTCPK
1.350
NaN%
Closed 09:30 02/12 EST
OPEN
--
PREV CLOSE
1.350
HIGH
--
LOW
--
VOLUME
--
TURNOVER
--
52 WEEK HIGH
5.34
52 WEEK LOW
0.965
MARKET CAP
1.74B
P/E (TTM)
-15.9574
1D
5D
1M
3M
1Y
5Y
1D
High Survival Rates With Ryoncil® in EIND Program Emphasize Importance of Earlier Use in Both Children and Adults With SR-aGvHD
Barchart · 1d ago
Analysts Offer Insights on Healthcare Companies: Moderna (MRNA), Mesoblast Limited (OtherMEOBF) and Wave Life Sciences (WVE)
TipRanks · 02/03 14:10
Analysts Offer Insights on Healthcare Companies: Thermo Fisher (TMO) and Mesoblast Limited (OtherMEOBF)
TipRanks · 01/29 23:40
Ryoncil® Net Revenues Increase for the Quarter to US$30M
Barchart · 01/28 17:54
Largest borrow rate increases among liquid names
TipRanks · 01/28 13:45
Mesoblast’s Ryoncil Shows Strong Early Survival in Real-World Use as U.S. Rollout Expands
TipRanks · 01/27 02:09
JPMorgan Ceases to Be Substantial Holder in Mesoblast
TipRanks · 01/26 22:33
Real-World Commercial Experience with Ryoncil® Shows 84% Survival of Children with SR-aGvHD After Completing 28-Days of Treatment
Barchart · 01/26 17:45
More
About MEOBF
Mesoblast Limited is an Australia-based company. The Company is engaged in developing allogeneic (off-the-shelf) cellular medicines for the treatment of severe and life-threatening inflammatory conditions. The Company has developing a range of late-stage product candidates, derived from its first and second generation proprietary mesenchymal lineage cell therapy technology platforms therapies for distinct indications. The Company’s Ryoncil (remestemcel-L-rknd) is an allogeneic bone marrow-derived mesenchymal stromal cell (MSC) therapy. Its other product candidate is Revascor (rexlemestrocel-L). Rexlemestrocel-L is second generation mesenchymal lineage precursor cell product platform and is in late-stage development for treatment of: chronic heart failure (chf) and chronic low back pain (clbp) due to degenerative disc disease. The two products have been commercialized in Japan and Europe by the Company's licensees.

Webull offers Mesoblast Ltd stock information, including OTCPK: MEOBF real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, MEOBF stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading MEOBF stock methods without spending real money on the virtual paper trading platform.